Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China

Shang, Penghui, Xia, Yinyin, Liu, Feiying, Wang, Xiaomeng, Yuan, Yanli, Hu, Daiyu, Tu, Dehua, Chen, Yixin, Deng, Peiyuan, Cheng, Shiming, Zhou, Lin, Ma, Yu, Zhu, Lizhen, Gao, Weiwei, Wang, Hongyuan, Chen, Dafang, Yang, Li, He, Pingping, Wu, Shanshan, Tang, Shaowen, Lv, Xiaozhen, Shu, Zheng, Zhang, Yuan, Yang, Zhirong, Chen, Yan, Li, Na, Sun, Feng, Li, Xiaoting, He, Yingjian, Garner, Paul ORCID: https://orcid.org/0000-0002-0607-6941 and Zhan, Siyan (2011) 'Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China'. PLoS ONE, Vol 6, Issue 7, e21836.

Preview

Text Plos_ONE_6_7_e21836.pdf - Published Version Available under License Creative Commons Attribution. Download (90kB)

Abstract

Background

Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China.

Methodology/Principal Findings

In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%–3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69–15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI,1.23–3.60) risk of prolonged intensive treatment phase.

Conclusions/Significance

ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI.

Item Type:	Article
Subjects:	WF Respiratory System > Tuberculosis > WF 200 Tuberculosis (General) WF Respiratory System > Tuberculosis > WF 360 Drug therapy
Faculty: Department:	Groups (2002 - 2012) > International Health Group
Digital Object Identifer (DOI):	https://doi.org/10.1371/journal.pone.0021836
Depositing User:	Faye Moody
Date Deposited:	02 Apr 2012 11:40
Last Modified:	06 Sep 2019 10:14
URI:	https://archive.lstmed.ac.uk/id/eprint/2822

Statistics

View details

Actions (login required)

Edit Item